BR112023000603A2 - Proteínas sars-cov-2, anticorpos anti-sars-cov-2 e métodos de uso dos mesmos - Google Patents
Proteínas sars-cov-2, anticorpos anti-sars-cov-2 e métodos de uso dos mesmosInfo
- Publication number
- BR112023000603A2 BR112023000603A2 BR112023000603A BR112023000603A BR112023000603A2 BR 112023000603 A2 BR112023000603 A2 BR 112023000603A2 BR 112023000603 A BR112023000603 A BR 112023000603A BR 112023000603 A BR112023000603 A BR 112023000603A BR 112023000603 A2 BR112023000603 A2 BR 112023000603A2
- Authority
- BR
- Brazil
- Prior art keywords
- cov
- sars
- antibodies
- proteins
- methods
- Prior art date
Links
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 title abstract 2
- 101710198474 Spike protein Proteins 0.000 abstract 2
- 239000013638 trimer Substances 0.000 abstract 2
- 241001678559 COVID-19 virus Species 0.000 abstract 1
- 229940096437 Protein S Drugs 0.000 abstract 1
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
PROTEÍNAS SARS-COV-2, ANTICORPOS ANTI-SARS-COV-2 E MÉTODOS DE USO DOS MESMOS. A presente invenção refere-se a proteínas spike de SARS-CoV-2 e trímeros contendo tais proteínas spike. A presente invenção também se refere a anticorpos e fragmentos de ligação a antígeno dos mesmos que se ligam especificamente à proteína spike de SARS-CoV-2. As proteínas, trímeros e anticorpos podem ser usados, por exemplo, para detectar anticorpos anti-SARS-CoV-2 em amostras obtidas de um indivíduo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063054104P | 2020-07-20 | 2020-07-20 | |
PCT/EP2021/070176 WO2022018040A2 (en) | 2020-07-20 | 2021-07-19 | Sars-cov-2 proteins, anti-sars-cov-2 antibodies, and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023000603A2 true BR112023000603A2 (pt) | 2023-01-31 |
Family
ID=77274776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023000603A BR112023000603A2 (pt) | 2020-07-20 | 2021-07-19 | Proteínas sars-cov-2, anticorpos anti-sars-cov-2 e métodos de uso dos mesmos |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230279078A1 (pt) |
EP (1) | EP4182343A2 (pt) |
JP (1) | JP2023534520A (pt) |
KR (1) | KR20230038783A (pt) |
CN (1) | CN116507636A (pt) |
AU (1) | AU2021313348A1 (pt) |
BR (1) | BR112023000603A2 (pt) |
CA (1) | CA3188938A1 (pt) |
IL (1) | IL299757A (pt) |
WO (1) | WO2022018040A2 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023144779A1 (en) * | 2022-01-28 | 2023-08-03 | Pfizer Inc. | Coronavirus antigen variants |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
ATE151110T1 (de) | 1988-09-02 | 1997-04-15 | Protein Eng Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
JP3672306B2 (ja) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二量体受容体ライブラリー |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
ATE275198T1 (de) | 1991-12-02 | 2004-09-15 | Medical Res Council | Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
WO1995020401A1 (en) | 1994-01-31 | 1995-08-03 | Trustees Of Boston University | Polyclonal antibody libraries |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
EP1539233B1 (en) | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
KR101206206B1 (ko) * | 2003-07-22 | 2012-11-29 | 크루셀 홀란드 비.브이. | 사스-코로나바이러스에 대한 결합분자 및 그것의 용도 |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
CA2697193C (en) | 2007-09-14 | 2017-06-06 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
AU2011279073B2 (en) | 2010-07-16 | 2016-06-09 | Adimab, Llc | Antibody libraries |
-
2021
- 2021-07-19 WO PCT/EP2021/070176 patent/WO2022018040A2/en active Application Filing
- 2021-07-19 IL IL299757A patent/IL299757A/en unknown
- 2021-07-19 KR KR1020237005579A patent/KR20230038783A/ko active Search and Examination
- 2021-07-19 US US18/006,054 patent/US20230279078A1/en active Pending
- 2021-07-19 CA CA3188938A patent/CA3188938A1/en active Pending
- 2021-07-19 AU AU2021313348A patent/AU2021313348A1/en active Pending
- 2021-07-19 JP JP2023503410A patent/JP2023534520A/ja active Pending
- 2021-07-19 EP EP21752505.4A patent/EP4182343A2/en active Pending
- 2021-07-19 BR BR112023000603A patent/BR112023000603A2/pt unknown
- 2021-07-19 CN CN202180050085.2A patent/CN116507636A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230279078A1 (en) | 2023-09-07 |
CA3188938A1 (en) | 2022-01-27 |
KR20230038783A (ko) | 2023-03-21 |
WO2022018040A3 (en) | 2022-04-14 |
EP4182343A2 (en) | 2023-05-24 |
IL299757A (en) | 2023-03-01 |
AU2021313348A1 (en) | 2023-03-09 |
JP2023534520A (ja) | 2023-08-09 |
CN116507636A (zh) | 2023-07-28 |
WO2022018040A2 (en) | 2022-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022017986A2 (pt) | Anticorpos anticoronavírus e métodos de uso | |
PH12021550793A1 (en) | Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments | |
BR112018003326A2 (pt) | anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos | |
EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
BR112018071153A2 (pt) | anticorpos anti-vista humano e uso dos mesmos | |
MA40801A1 (fr) | Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123 | |
EA201892325A1 (ru) | Композиции и способы детектирования белков клетки-хозяина | |
MX2022014422A (es) | Anticuerpos contra el sars-cov-2 y metodos de seleccion y uso de los mismos. | |
BR112022000216A2 (pt) | Anticorpos direcionados a dll3 e usos dos mesmos | |
BR112016017764A2 (pt) | anticorpo antidengue de amplo espectro | |
CL2020000087A1 (es) | Cromatografía. | |
BR112021016398A2 (pt) | Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer | |
MX2020011312A (es) | Anticuerpo de repetición de dipéptidos (dpr) anti poliglicina-alanina (poli-ga) derivado de humanos. | |
BR112022001733A2 (pt) | Anticorpos anti-ms4a4a e métodos de uso dos mesmos | |
BR112021021281A2 (pt) | Anticorpo monoclonal que se liga especificamente ao gitr | |
BR112021016791A2 (pt) | Proteínas de ligação de antígenos que se ligam a bcma | |
EA202092088A1 (ru) | Антитела анти-phf-тау и их применение | |
EA202191931A1 (ru) | Способ характеризации видимых и/или невидимых частиц в биологических препаратах | |
EA201991506A1 (ru) | Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов | |
BR112023000603A2 (pt) | Proteínas sars-cov-2, anticorpos anti-sars-cov-2 e métodos de uso dos mesmos | |
BR112022020410A2 (pt) | Anticorpos anti-phf-tau e usos dos mesmos | |
BR112023019546A2 (pt) | Anticorpos anti-tau e usos dos mesmos | |
EA202090627A1 (ru) | Способы оценки конъюгатов антитела и лекарственного препарата | |
BR112022005410A2 (pt) | Métodos e composições compreendendo um anticorpo monoclonal anti-ctla4 com proteínas de célula hospedeira reduzidas e estabilidade de polissorbato 80 aumentada | |
GB2541596A (en) | Method and composition for determining specific antibody responses to species of filovirus |